Efficacy and safety of a selective partial agonist for nociception/orphanin-FQ peptide (NOP) receptors in patients with insomnia disorder.

ABSTRACT:

Aims

Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well-being. Although pharmacologic options exist to treat insomnia, the health-related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant treatment gap. Sunobinop, an oral, selective, potent, partial agonist of the nociceptin receptor (NOP), was evaluated for efficacy and safety in the treatment of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) insomnia disorder.

Methods

In this randomized, double-blind, repeat-dose, crossover, Phase 1 study, 30 patients were assigned to treatment with sunobinop 0.5 mg, 1.0 mg, 3.0 mg and 6.0 mg and

SUBMITTER: Whiteside GT 

PROVIDER: S-EPMC12746404 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature